5947.0000 -50.50 (-0.84%)
NSE Mar 30, 2026 15:31 PM
Volume: 492.2K
 

Deven Choksey
We have revised our FY26E/FY27E EPS estimates by -14.9%/-22.7%, respectively, as we factor in subdued growth traction in Generic API segment, lower other income and higher depreciation expenses on account of higher investments in its facilities.
Number of FII/FPI investors decreased from 897 to 868 in Dec 2025 qtr
More from Divi's Laboratories Ltd.
Recommended